1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
60A737F33816C6FE5652580290045CD10
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/0A737F33816C6FE5652580290045CD10!OpenDocument
18
19OpenDocument
2018.97.14.81
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Patient Focused Services » Patient Advocacy Groups

Document Excerpt: Collaborating with Patient Advocacy Groups: Regulatory Impact, Technology Use & Future Trends

DB Image

ID: MD-529


Features:

30 Info Graphics

7 Data Graphics

50+ Metrics

16 Narratives

18 Best Practices


Pages/Slides: 4


Published: Pre-2020


Delivery Format: Online PDF Document


 

License Options:


Download FREE Excerpt

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
To download this excerpt, click "Download Free Excerpt".

To return to the study abstract to purchase the full study – click here

This excerpt includes research findings and metrics from document #5428 "Collaborating with Patient Advocacy Groups: Regulatory Impact, Technology Use & Future Trends”


Industries Profiled:
Biopharmaceutical; Pharmaceutical; Medical; Manufacturing; Biotech; Consumer Products; Diagnostic; Medical Device; Research; Health Care


Companies Profiled:
Alnylam Pharmaceuticals; Astellas; Baldwin Area Medical Center; Bayer; Boehringer Ingelheim; Covance; Forum Pharmaceuticals; Genzyme; Horizon Pharma; Johnson & Johnson; Lundbeck; Mallinckrodt; Natera; Novartis; Parkway Pantai; Pfizer; Pharmacyclics; Spark Therapeutics; Teva Pharmaceutical Industries Ltd; UCB Pharma; Zogenix

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.